3-cyano-4-phenyl-6-(3-bromo-6-hydroxyphenyl)-2-pyridone : A member of the class of pyridones that is 2-pyridone carrying cyano, phenyl and 3-bromo-6-hydroxyphenyl substituents at positions 3, 4 and 6 respectively [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 1235170 |
| CHEMBL ID | 391586 |
| CHEBI ID | 86453 |
| SCHEMBL ID | 15129618 |
| Synonym |
|---|
| vrv , |
| 6-(5-bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carbonitrile |
| 2OBJ |
| pyridone-based compound, 1 |
| chembl391586 , |
| bdbm26673 |
| 6-(5-bromo-2-hydroxy-phenyl)-2-oxo-4-phenyl-1h-pyridine-3-carbonitrile |
| chebi:86453 , |
| DB08705 |
| HMS3229J17 |
| 6-(5-bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1h-pyridine-3-carbonitrile |
| CCG-101294 |
| tcs pim-1 1 |
| HY-18086 |
| CS-2043 |
| mfcd00276275 |
| 491871-58-0 |
| S1050 |
| c18h11brn2o2 |
| SCHEMBL15129618 |
| 3-cyano-4-phenyl-6-(3-bromo-6-hydroxy)phenyl-2(1h)-pyridone |
| 3-cyano-4-phenyl-6-(3-bromo-6-hydroxyphenyl)-2-pyridone |
| pim1i |
| tcs pim-11 |
| AKOS024457365 |
| EX-A308 |
| sc 204330;sc-204330;sc204330 |
| BCP15861 |
| FT-0700318 |
| Q27097891 |
| AS-16824 |
| tcs-pim-1-1 |
| HMS3742G19 |
| A871835 |
| AC-35434 |
| 6-(5-bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1,2-dihydro-pyridine-3-carbonitrile |
| Class | Description |
|---|---|
| pyridone | |
| bromophenol | A halophenol that is any phenol containing one or more covalently bonded bromine atoms. |
| nitrile | A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1 | Homo sapiens (human) | IC50 (µMol) | 0.0500 | 0.0500 | 0.0500 | 0.0500 | AID977608 |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | IC50 (µMol) | 0.0500 | 0.0004 | 0.8871 | 10.0000 | AID1798719; AID306161; AID351984; AID418380; AID437472; AID706714 |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.0002 | 0.4653 | 9.7000 | AID306164 |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.0002 | 0.6813 | 9.7000 | AID306163 |
| Serine/threonine-protein kinase pim-2 | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.0047 | 0.5214 | 5.1000 | AID306162 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Baculoviral IAP repeat-containing protein 5 | Homo sapiens (human) | Kd | 5.3500 | 5.0000 | 6.2333 | 8.0000 | AID295444; AID437473 |
| 5-hydroxytryptamine receptor 3A | Cavia porcellus (domestic guinea pig) | Kd | 5.0000 | 0.0501 | 3.2819 | 8.0000 | AID295444 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1811 | Experimentally measured binding affinity data derived from PDB | 2007 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6 | Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2007 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6 | Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. |
| AID295444 | Binding affinity to human survivin expressed in Escherichia coli BL21 cells after 30 mins | 2007 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11 | Discovery of a novel small molecule binding site of human survivin. |
| AID418380 | Inhibition of Pim1 after 15 mins by scintillation counting-based competition assay in presence of 25 uM [gamma33P]ATP | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7 | Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. |
| AID306161 | Inhibition of Pim1 kinase | 2007 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6 | Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. |
| AID306162 | Inhibition of Pim2 kinase | 2007 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6 | Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. |
| AID706714 | Competitive inhibition of PIM1 in presence of ATP | 2012 | Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19 | Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy. |
| AID306164 | Inhibition of MEK2 kinase | 2007 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6 | Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. |
| AID306163 | Inhibition of MEK1 kinase | 2007 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6 | Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. |
| AID437473 | Inhibition of survivin | 2010 | European journal of medicinal chemistry, Jan, Volume: 45, Issue:1 | Discovery of colon tumor cell growth inhibitory agents through a combinatorial approach. |
| AID351984 | Inhibition of Pim1 assessed as [32P] incorporation preincubated for 15 mins before ATP substrate addition by coupled spectrophotometric assay | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase. |
| AID437472 | Inhibition of PIM1 | 2010 | European journal of medicinal chemistry, Jan, Volume: 45, Issue:1 | Discovery of colon tumor cell growth inhibitory agents through a combinatorial approach. |
| AID1798719 | Radioactive Filter Plate Assay from Article 10.1016/j.bmcl.2006.12.086: \\Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase.\\ | 2007 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6 | Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.33) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||